Biofil Chemicals & Pharmaceuticals Ltd
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd manufactures pharmaceutical bulk drugs[1]
- Market Cap ₹ 119 Cr.
- Current Price ₹ 72.6
- High / Low ₹ 79.0 / 41.0
- Stock P/E 180
- Book Value ₹ 10.9
- Dividend Yield 0.00 %
- ROCE 4.73 %
- ROE 3.28 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 6.69 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.10% over last 3 years.
- Company has high debtors of 249 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6.27 | 6.01 | 7.17 | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 38.45 | |
5.88 | 5.00 | 6.21 | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 37.19 | |
Operating Profit | 0.39 | 1.01 | 0.96 | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 1.26 |
OPM % | 6.22% | 16.81% | 13.39% | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 3.28% |
0.04 | 0.06 | 0.06 | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.11 | |
Interest | 0.08 | 0.19 | 0.15 | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.03 |
Depreciation | 0.19 | 0.21 | 0.22 | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.44 |
Profit before tax | 0.16 | 0.67 | 0.65 | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.90 |
Tax % | 6.25% | 19.40% | 20.00% | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | |
0.15 | 0.54 | 0.52 | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.66 | |
EPS in Rs | 0.09 | 0.33 | 0.32 | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.41 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 19% |
3 Years: | 0% |
TTM: | 113% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 4% |
3 Years: | -23% |
TTM: | 100% |
Stock Price CAGR | |
---|---|
10 Years: | 43% |
5 Years: | 58% |
3 Years: | 1% |
1 Year: | 64% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 5% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
Reserves | -9.44 | -8.91 | -8.41 | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.40 |
2.49 | 2.79 | 2.87 | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.53 | 0.56 | |
4.79 | 3.35 | 3.87 | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 23.99 | |
Total Liabilities | 14.11 | 13.50 | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.41 | 42.22 |
9.10 | 9.17 | 9.17 | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.79 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
5.01 | 4.33 | 5.43 | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.41 | 33.43 | |
Total Assets | 14.11 | 13.50 | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.41 | 42.22 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.21 | -0.12 | 0.21 | 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | |
-0.82 | -0.30 | -0.24 | -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | |
1.19 | 0.30 | 0.07 | 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | |
Net Cash Flow | 0.16 | -0.12 | 0.04 | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 239.26 | 202.85 | 208.72 | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 |
Inventory Days | 16.35 | 31.15 | 20.53 | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 |
Days Payable | 350.88 | 302.71 | 276.79 | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 |
Cash Conversion Cycle | -95.26 | -68.71 | -47.54 | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 |
Working Capital Days | -1.16 | 51.62 | 70.25 | 137.65 | 86.47 | 126.46 | 150.90 | 76.69 | 70.32 | 68.51 | 132.76 | 111.42 |
ROCE % | 2.77% | 8.83% | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% |
Documents
Announcements
- Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31St March, 2024. 15 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 9 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Certificate received from RTA pursuant to Regulation 74(5) of the SEBI (Depository and Participants), Regulation, 2018 for the Quarter ended 31.03.2024.
- Submission Of Compliance Certificate Under Regulation 7(3) SEBI Listing Obligation And Disclosure Requirements Regulations 2015 For The Year Ended 31.03.2024. 3 Apr
-
Announcement under Regulation 30 (LODR)-Change in Management
29 Mar - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for completion of tenure of second and final term of Smt. Shaila Jain (DIN: 00326130), as …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company deals in manufacturing and trading of pharmaceutical and also manufactures plastic products required for packing pharmaceutical and other plastic products. Further, it also deals in providing job work facility in respect of manufacturing of pharmaceuticals drugs via 2 units viz. Pharmaceutical Division & Chemicals Division.